Concepts (217)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 9 | 2018 | 319 | 2.010 |
Why?
|
| Neuroendocrine Tumors | 3 | 2018 | 23 | 0.830 |
Why?
|
| Pancreatectomy | 5 | 2017 | 86 | 0.700 |
Why?
|
| Pancreaticoduodenectomy | 3 | 2018 | 56 | 0.660 |
Why?
|
| Liver Neoplasms | 3 | 2017 | 278 | 0.630 |
Why?
|
| Carcinoid Tumor | 2 | 2017 | 14 | 0.630 |
Why?
|
| Metastasectomy | 1 | 2018 | 4 | 0.620 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2017 | 405 | 0.510 |
Why?
|
| Esophageal Neoplasms | 2 | 2016 | 77 | 0.490 |
Why?
|
| Hospitals, Low-Volume | 1 | 2014 | 17 | 0.470 |
Why?
|
| Hospitals, High-Volume | 1 | 2014 | 32 | 0.460 |
Why?
|
| Pancreatic Cyst | 2 | 2012 | 23 | 0.410 |
Why?
|
| Pyloric Stenosis | 1 | 2012 | 4 | 0.400 |
Why?
|
| Esophagoscopy | 1 | 2012 | 28 | 0.390 |
Why?
|
| Esophagectomy | 2 | 2012 | 44 | 0.390 |
Why?
|
| Dendritic Cell Sarcoma, Follicular | 1 | 2011 | 1 | 0.390 |
Why?
|
| Catheterization | 1 | 2012 | 111 | 0.380 |
Why?
|
| Survival Rate | 7 | 2018 | 790 | 0.380 |
Why?
|
| General Surgery | 2 | 2012 | 188 | 0.380 |
Why?
|
| Catheter Ablation | 2 | 2017 | 141 | 0.350 |
Why?
|
| Advisory Committees | 1 | 2010 | 107 | 0.340 |
Why?
|
| Lymph Nodes | 2 | 2017 | 212 | 0.330 |
Why?
|
| Middle Aged | 22 | 2018 | 16404 | 0.330 |
Why?
|
| Neoplasm Staging | 8 | 2017 | 455 | 0.310 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2008 | 63 | 0.300 |
Why?
|
| Rectal Neoplasms | 2 | 2012 | 98 | 0.280 |
Why?
|
| Aged | 18 | 2018 | 13464 | 0.280 |
Why?
|
| Colonic Neoplasms | 2 | 2012 | 215 | 0.270 |
Why?
|
| Male | 24 | 2018 | 27776 | 0.270 |
Why?
|
| Aged, 80 and over | 11 | 2017 | 5149 | 0.240 |
Why?
|
| Proportional Hazards Models | 4 | 2018 | 672 | 0.240 |
Why?
|
| Decision Making | 1 | 2008 | 393 | 0.240 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2017 | 302 | 0.230 |
Why?
|
| Humans | 30 | 2018 | 59836 | 0.220 |
Why?
|
| Liver Cirrhosis | 1 | 2005 | 159 | 0.220 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2005 | 168 | 0.220 |
Why?
|
| Female | 23 | 2018 | 31113 | 0.220 |
Why?
|
| Adult | 13 | 2018 | 15888 | 0.210 |
Why?
|
| Hepatectomy | 2 | 2017 | 59 | 0.200 |
Why?
|
| Stomach Neoplasms | 2 | 2017 | 74 | 0.190 |
Why?
|
| Adenocarcinoma | 3 | 2017 | 324 | 0.190 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2018 | 389 | 0.190 |
Why?
|
| United States | 7 | 2018 | 7577 | 0.190 |
Why?
|
| Esophagogastric Junction | 2 | 2017 | 15 | 0.180 |
Why?
|
| Palliative Care | 1 | 2002 | 212 | 0.180 |
Why?
|
| Patient Selection | 1 | 2002 | 448 | 0.170 |
Why?
|
| Postoperative Complications | 4 | 2016 | 1142 | 0.170 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 356 | 0.160 |
Why?
|
| Treatment Outcome | 7 | 2017 | 5207 | 0.160 |
Why?
|
| Chemoradiotherapy | 2 | 2016 | 49 | 0.160 |
Why?
|
| Pancreas | 2 | 2017 | 146 | 0.160 |
Why?
|
| Neoadjuvant Therapy | 2 | 2016 | 71 | 0.160 |
Why?
|
| Prognosis | 6 | 2017 | 1584 | 0.150 |
Why?
|
| Follow-Up Studies | 7 | 2017 | 2341 | 0.150 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 196 | 0.150 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2017 | 8 | 0.150 |
Why?
|
| Fluorouracil | 2 | 2017 | 54 | 0.150 |
Why?
|
| Clinical Competence | 1 | 2002 | 685 | 0.140 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 36 | 0.140 |
Why?
|
| Retrospective Studies | 9 | 2016 | 6042 | 0.140 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2016 | 36 | 0.130 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2017 | 105 | 0.130 |
Why?
|
| Failure to Thrive | 1 | 2016 | 7 | 0.130 |
Why?
|
| Dehydration | 1 | 2016 | 14 | 0.130 |
Why?
|
| Transitional Care | 1 | 2016 | 26 | 0.130 |
Why?
|
| Cathepsin L | 1 | 2015 | 20 | 0.130 |
Why?
|
| Postoperative Care | 1 | 2016 | 112 | 0.130 |
Why?
|
| Th17 Cells | 1 | 2015 | 56 | 0.120 |
Why?
|
| Intraoperative Complications | 2 | 2013 | 82 | 0.120 |
Why?
|
| Gallbladder Neoplasms | 2 | 2006 | 17 | 0.120 |
Why?
|
| Endoscopy, Digestive System | 2 | 2015 | 30 | 0.120 |
Why?
|
| Cell Cycle | 1 | 2017 | 379 | 0.120 |
Why?
|
| Cysteine Endopeptidases | 1 | 2015 | 90 | 0.120 |
Why?
|
| Pancreatitis | 1 | 2015 | 101 | 0.120 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2015 | 117 | 0.120 |
Why?
|
| Video Recording | 2 | 2012 | 126 | 0.120 |
Why?
|
| Postoperative Period | 1 | 2014 | 125 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 483 | 0.110 |
Why?
|
| Lymphatic Metastasis | 3 | 2017 | 68 | 0.110 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2015 | 256 | 0.110 |
Why?
|
| Photons | 1 | 2013 | 26 | 0.110 |
Why?
|
| Deoxycytidine | 1 | 2013 | 39 | 0.110 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2013 | 38 | 0.110 |
Why?
|
| Risk Factors | 4 | 2017 | 5040 | 0.110 |
Why?
|
| Databases, Factual | 2 | 2014 | 843 | 0.110 |
Why?
|
| Gastric Outlet Obstruction | 1 | 2012 | 2 | 0.100 |
Why?
|
| Pylorus | 1 | 2012 | 9 | 0.100 |
Why?
|
| Barium Sulfate | 1 | 2012 | 18 | 0.100 |
Why?
|
| Operating Rooms | 1 | 2012 | 53 | 0.100 |
Why?
|
| Retreatment | 1 | 2012 | 45 | 0.100 |
Why?
|
| Vincristine | 1 | 2011 | 26 | 0.100 |
Why?
|
| Patient Readmission | 1 | 2016 | 422 | 0.100 |
Why?
|
| Cyclophosphamide | 1 | 2011 | 71 | 0.100 |
Why?
|
| Prednisone | 1 | 2011 | 80 | 0.090 |
Why?
|
| Doxorubicin | 1 | 2011 | 99 | 0.090 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2012 | 141 | 0.090 |
Why?
|
| Education, Medical, Continuing | 1 | 2012 | 98 | 0.090 |
Why?
|
| Pancreaticojejunostomy | 1 | 2010 | 5 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2017 | 619 | 0.090 |
Why?
|
| Pancreatic Ducts | 1 | 2010 | 30 | 0.090 |
Why?
|
| Surgery Department, Hospital | 1 | 2010 | 20 | 0.090 |
Why?
|
| Disease-Free Survival | 3 | 2017 | 233 | 0.090 |
Why?
|
| Congresses as Topic | 1 | 2010 | 74 | 0.090 |
Why?
|
| Radiography | 1 | 2012 | 513 | 0.090 |
Why?
|
| Needles | 1 | 2010 | 64 | 0.090 |
Why?
|
| Cell Differentiation | 1 | 2015 | 1297 | 0.080 |
Why?
|
| Diabetes Mellitus | 1 | 2014 | 538 | 0.080 |
Why?
|
| Contrast Media | 1 | 2012 | 414 | 0.080 |
Why?
|
| Safety Management | 1 | 2010 | 143 | 0.080 |
Why?
|
| Cystadenoma, Papillary | 1 | 2008 | 1 | 0.080 |
Why?
|
| Cystadenoma, Mucinous | 1 | 2008 | 5 | 0.080 |
Why?
|
| Time Factors | 2 | 2014 | 3593 | 0.080 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2008 | 9 | 0.080 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2008 | 12 | 0.080 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2008 | 30 | 0.080 |
Why?
|
| Endosonography | 1 | 2008 | 33 | 0.080 |
Why?
|
| Pancreatic Diseases | 1 | 2008 | 39 | 0.080 |
Why?
|
| Societies, Medical | 1 | 2010 | 331 | 0.080 |
Why?
|
| Adolescent | 3 | 2014 | 5941 | 0.070 |
Why?
|
| Hematologic Neoplasms | 1 | 2008 | 45 | 0.070 |
Why?
|
| Graft vs Host Disease | 1 | 2008 | 99 | 0.070 |
Why?
|
| Cisplatin | 2 | 2017 | 119 | 0.070 |
Why?
|
| Databases as Topic | 1 | 2006 | 53 | 0.070 |
Why?
|
| Liver Function Tests | 1 | 2005 | 36 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2008 | 909 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2008 | 328 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 1098 | 0.060 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2005 | 87 | 0.060 |
Why?
|
| Cardia | 1 | 2004 | 2 | 0.060 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2017 | 56 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2016 | 1918 | 0.060 |
Why?
|
| Multivariate Analysis | 3 | 2014 | 925 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2008 | 1461 | 0.060 |
Why?
|
| Cholecystectomy | 1 | 2004 | 31 | 0.060 |
Why?
|
| Evidence-Based Medicine | 1 | 2006 | 454 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2003 | 77 | 0.050 |
Why?
|
| Laser Therapy | 1 | 2002 | 36 | 0.050 |
Why?
|
| Laparoscopy | 1 | 2005 | 392 | 0.050 |
Why?
|
| Survival Analysis | 3 | 2010 | 553 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2012 | 523 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2017 | 3110 | 0.040 |
Why?
|
| Epirubicin | 1 | 2017 | 2 | 0.040 |
Why?
|
| Leucovorin | 1 | 2017 | 9 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2017 | 24 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2017 | 35 | 0.040 |
Why?
|
| Antineoplastic Agents | 2 | 2017 | 647 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 2017 | 182 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2017 | 87 | 0.030 |
Why?
|
| Anorexia | 1 | 2016 | 6 | 0.030 |
Why?
|
| Celecoxib | 1 | 2016 | 14 | 0.030 |
Why?
|
| Young Adult | 3 | 2012 | 4370 | 0.030 |
Why?
|
| Chemotherapy-Induced Febrile Neutropenia | 1 | 2016 | 3 | 0.030 |
Why?
|
| Mutation | 2 | 2017 | 2464 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2005 | 2049 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 182 | 0.030 |
Why?
|
| Camptothecin | 1 | 2016 | 23 | 0.030 |
Why?
|
| Deglutition Disorders | 1 | 2016 | 43 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 279 | 0.030 |
Why?
|
| Serpins | 1 | 2015 | 17 | 0.030 |
Why?
|
| Nausea | 1 | 2016 | 109 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 345 | 0.030 |
Why?
|
| Necrosis | 1 | 2015 | 140 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 324 | 0.030 |
Why?
|
| Disease Management | 1 | 2017 | 220 | 0.030 |
Why?
|
| Age of Onset | 1 | 2014 | 171 | 0.030 |
Why?
|
| Capecitabine | 1 | 2013 | 10 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2013 | 54 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2017 | 310 | 0.030 |
Why?
|
| Radiation Injuries | 1 | 2013 | 57 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2017 | 1379 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1059 | 0.030 |
Why?
|
| Effect Modifier, Epidemiologic | 1 | 2012 | 8 | 0.030 |
Why?
|
| Molecular Epidemiology | 1 | 2012 | 26 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 2012 | 51 | 0.030 |
Why?
|
| Logistic Models | 1 | 2016 | 1252 | 0.030 |
Why?
|
| Cystadenoma, Serous | 1 | 2012 | 4 | 0.020 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2012 | 53 | 0.020 |
Why?
|
| ras Proteins | 1 | 2012 | 78 | 0.020 |
Why?
|
| Ergonomics | 1 | 2012 | 77 | 0.020 |
Why?
|
| Learning Curve | 1 | 2012 | 23 | 0.020 |
Why?
|
| Efficiency, Organizational | 1 | 2012 | 95 | 0.020 |
Why?
|
| Algorithms | 1 | 2017 | 998 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2012 | 486 | 0.020 |
Why?
|
| Comorbidity | 1 | 2014 | 1091 | 0.020 |
Why?
|
| Incidence | 1 | 2014 | 1246 | 0.020 |
Why?
|
| Nanoparticles | 1 | 2017 | 499 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2015 | 2099 | 0.020 |
Why?
|
| Dilatation, Pathologic | 1 | 2010 | 28 | 0.020 |
Why?
|
| Continuity of Patient Care | 1 | 2012 | 173 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2012 | 316 | 0.020 |
Why?
|
| Occupational Health | 1 | 2012 | 186 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2010 | 104 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2015 | 1997 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2012 | 273 | 0.020 |
Why?
|
| Medical Errors | 1 | 2012 | 193 | 0.020 |
Why?
|
| World Health Organization | 1 | 2010 | 30 | 0.020 |
Why?
|
| Probability | 1 | 2010 | 172 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2012 | 333 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 402 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2010 | 577 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 927 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 1128 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 3207 | 0.020 |
Why?
|
| Animals | 2 | 2017 | 19725 | 0.020 |
Why?
|
| Communication | 1 | 2012 | 556 | 0.020 |
Why?
|
| Acute Disease | 1 | 2008 | 659 | 0.020 |
Why?
|
| Malignant Carcinoid Syndrome | 1 | 2006 | 1 | 0.020 |
Why?
|
| Respiratory Tract Neoplasms | 1 | 2006 | 3 | 0.020 |
Why?
|
| Registries | 1 | 2010 | 804 | 0.020 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2006 | 30 | 0.020 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2006 | 33 | 0.020 |
Why?
|
| Gastrectomy | 1 | 2004 | 34 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2010 | 2461 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2006 | 242 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2006 | 461 | 0.010 |
Why?
|
| Mice | 1 | 2015 | 10309 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2004 | 1030 | 0.010 |
Why?
|